Guardant Health (GH) said Thursday that the US Food and Drug Administration has approved Guardant360 CDx as a companion diagnostic for Boehringer Ingelheim's Hernexeos therapy in adults with HER2-mutant advanced non-small cell lung cancer.
The Guardant360 CDx is a liquid biopsy test that identifies patients with HER2 mutations who may be eligible for treatment with Hernexeos, Guardant Health said.
Shares of the company were up 1.6% in Thursday premarket trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments